Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT01796795
Other study ID # GESRTCWA
Secondary ID
Status Suspended
Phase Phase 2
First received
Last updated
Start date September 2030
Est. completion date August 2033

Study information

Verified date September 2023
Source G&E Herbal Biotechnology Co., LTD
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II study is to evaluate the efficacy of SR-T100 gel in complete clearance of target warts at different concentrations (1.0% and 2.3% of SM in Solanum undatum plant extract) in patients with CW.


Recruitment information / eligibility

Status Suspended
Enrollment 102
Est. completion date August 2033
Est. primary completion date April 2033
Accepts healthy volunteers No
Gender All
Age group 17 Years and older
Eligibility Inclusion Criteria: 1. Age = 17 years old. 2. The diagnosis of CW is based on visual inspection by an experienced dermatologist. 3. Patient is selected = 5 CW lesions; each of the target lesion(s) needs to be = 15 mm in diameter. For patient with only 1 selected lesion, the size of target lesion needs to be measuring 2 to 15 mm in diameter. 4. Patient agrees to apply the study medication on target CW lesion(s) with an occlusive dressing for at least 20 hours per day. 5. Patient or the legally acceptable representative of patient under 20 years of age, is willing and able to provide written informed consent. 6. Patient agrees not to use wart-removing product/modality (prescription or over-the-counter) other than the study product during the course of the study; and is willing to refrain from using cosmetics or other topical products in the treatment area for the duration of the study. 7. Any non-target CW receiving wart-removing procedures including cryotherapy and surgical therapy should be at least 5 cm apart from the target lesions. 8. Patient is free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk to the patient. 9. Patient is judged to be in good health based upon the results of physical examinations (PEs), medical history, and safety laboratory tests. 10. Patient in good general health condition (performance status = 2 Eastern Cooperative Oncology Group (ECOG)). 11. Patient agrees to be photographed of the CW target lesion(s) and used of such data as part of the study package. 12. Female patient of childbearing potential should have a negative urine or serum pregnancy test at Screening day, and is willing to use effective contraception during the study. Exclusion Criteria: 1. The treatment area is located in any of the following areas: the eye area (including eyelids), lips, mouth cavity, nasal cavity,inner ear, soles of the feet, underneath the nails, and the anogenital area. 2. Patient had participated in a clinical study within 30 days prior to the Randomization visit, or is currently participating in another clinical study. 3. Patient had used any wart-removing product/modality in the treatment area within 30 days prior to the Randomization visit or received cryotherapy in the treatment area within 60 days prior to the Randomization visit. 4. Patient who has immune-compromised conditions, have required or will require systemic intake of immunosuppressive or immunomodulatory medication (oral or parental corticosteroids are included) within 30 days prior to the Randomization visit or during the course of the study. Routine use of inhaled or intranasal corticosteroids during the study is allowed. 5. Patient has clinically significant or unstable medical conditions (psychologically and physically) in any of the following listed situations: 1. Clinically significant peripheral vascular disease based on medical history. 2. Current uncontrolled infection, current skin infections and/or skin disorder in the treatment area other than CW and/or in the area surrounding the warts that may confound or affect study assessment procedure of the study endpoints. 3. Chronic or acute medical condition that, in the opinion of the investigator, may interfere with the study results or place the subject at undue risk (including human immunodeficiency virus, systemic lupus erythematosis, active viral hepatitis, etc.). 6. Patient is pregnant, plan to become pregnant, or is breastfeeding. 7. Patient has a history of allergy or sensitivity to Solanum undatum plant extract, SM, or SR-T100 gel excipients including carbomer, propylene glycol, and triethanolamine.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Vehicle gel
Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
SR-T100 gel with 1.0% of SM
Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
SR-T100 gel with 2.3% of SM
Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
G&E Herbal Biotechnology Co., LTD

Outcome

Type Measure Description Time frame Safety issue
Primary Total clearance rate of treated CW 16 weeks
Secondary Proportion of patient with at least 75% reduction in CW lesion counts 16 weeks
Secondary Proportion of patient with at least 50% reduction in lesion size (volume) 16 weeks
Secondary Mean of percent reduction in CW lesion counts from individual patient by visit 16 weeks
Secondary Mean of percent reduction in CW lesion size from individual patient by visit 16 weeks
Secondary CW recurrence rate 28 weeks
Secondary Time to complete clearance 16 weeks
Secondary Percent reduction for pooled lesion counts by visit 16 weeks
Secondary Safety: evaluate the changes occurring from baseline (Randomization visit) to EOT visit. including PE, vital sign, lab. test, local skin reaction, and adverse event, etc. 28 weeks
See also
  Status Clinical Trial Phase
Completed NCT03687372 - Study of A-101 Topical Solution for the Treatment of Common Warts Phase 3
Completed NCT03691831 - A Study of A-101 Topical Solution for the Treatment of Common Warts Phase 3
Completed NCT00328991 - Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts N/A
Completed NCT05115669 - Safety & Effectiveness of Wortie Freeze Plus in Common and Plantar Warts N/A
Completed NCT03487549 - Cantharidin and Occlusion in Verruca Epithelium Phase 2
Not yet recruiting NCT04288817 - Efficacy of Cryotherapy Combined With Intralesional Tuberculin PPD Versus Intralesional Tuberculin PPD in Treatment of Multiple Common Warts Phase 3
Active, not recruiting NCT05896215 - OM202JP Clinical Study of KNP2002 Phase 2
Completed NCT03278028 - A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts Phase 2
Completed NCT03812510 - Safety Study of A-101 Topical Solution for the Treatment of Common Warts Phase 3
Recruiting NCT05799157 - Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts Phase 2
Recruiting NCT06214559 - Evaluate the Effectiveness and the Safety of a Medical Device in the Treatment of Common Warts and Plantar Warts. N/A
Recruiting NCT03977753 - Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts Phase 4
Completed NCT03210337 - A Phase2 of A-101 Topical Solution in Subjects With Common Warts Phase 2
Completed NCT03183765 - Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Phase 4